专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL272723D0 Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis 未知
公开(公告)号：IL272723D0
公开(公告)日：2020-04-30
申请号：IL27272320
申请日：2020-02-17
申请人： JAYANTH JAYANTHY , ABBVIE INC , NEUROCRINE BIOSCIENCES INC , CHWALISZ KRISTOF , THOMAS JAMES W , CASTELLI HALEY JANE , GORDON KEITH , SNABES MICHAEL C , SOLIMAN AHMED M , FLORES OSCAR ANTUNEZ , JAIN RITA , NORTH JANINE D , PALAC HANNAH , PELOSO PAUL M , WILLIAMS LAURA A , SPENCE KEVIN C , MCCLELLAND GREGORY A , STEPANENKO ANNA V , OWENS CHAROLOTTE D , ZHANG GEOFF , METZGER DAVID , LI YANXIA , JU TZUCHI R , SHAO XI , NG WING KEUNG JUKI
发明人： JAYANTH JAYANTHY , CHWALISZ KRISTOF , THOMAS JAMES W , CASTELLI-HALEY JANE , GORDON KEITH , SNABES MICHAEL C , SOLIMAN AHMED M , FLORES OSCAR ANTUNEZ , JAIN RITA , NORTH JANINE D , PALAC HANNAH , PELOSO PAUL M , WILLIAMS LAURA A , SPENCE KEVIN C , MCCLELLAND GREGORY A , STEPANENKO ANNA V , OWENS CHAROLOTTE D , ZHANG GEOFF , METZGER DAVID , LI YANXIA , JU TZUCHI R , SHAO XI , NG WING-KEUNG JUKI
IPC分类号： A61K20060101
摘要： The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

2. 发明申请

WO2010127198A1 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER 审中-公开
标题翻译：制剂推荐药物的口服制剂
公开(公告)号：WO2010127198A1
公开(公告)日：2010-11-04
申请号：PCT/US2010/033085
申请日：2010-04-30
申请人： ABBOTT LABORATORIES , ABBOTT GMBH & CO. KG , CATRON, Nathaniel , FICKES, Michael , FISCHER, Cristina , GOKHALE, Rajeev , HAIGHT, Anthony R. , HEEMSTRA, Katherine , HILL, David , KNOBLOCH, Martin, Dr. , KOSTELAC, Drazen, Dr. , LAFOUNTAINE, Justin S. , LI, Yanxia , LIEPOLD, Bernd, Dr. , MARSH, Kennan , MILLER, Jonathan Mark , PACKHAEUSER, Claudia, Dr. , SANZGIRI, Yeshwant , SCHMITT, Eric , SHI, Yi , STEIGER, Norbert , TONG, Ping , WU, Huailiang , ZHANG, Geoff , ZHOU, Deliang
发明人： CATRON, Nathaniel , FICKES, Michael , FISCHER, Cristina , GOKHALE, Rajeev , HAIGHT, Anthony R. , HEEMSTRA, Katherine , HILL, David , KNOBLOCH, Martin, Dr. , KOSTELAC, Drazen, Dr. , LAFOUNTAINE, Justin S. , LI, Yanxia , LIEPOLD, Bernd, Dr. , MARSH, Kennan , MILLER, Jonathan Mark , PACKHAEUSER, Claudia, Dr. , SANZGIRI, Yeshwant , SCHMITT, Eric , SHI, Yi , STEIGER, Norbert , TONG, Ping , WU, Huailiang , ZHANG, Geoff , ZHOU, Deliang
IPC分类号： A61K9/00 , A61K31/5377 , A61K47/00 , A61K47/02 , A61K47/14 , A61K47/20
CPC分类号： A61K31/5377 , A61K9/08 , A61K9/10 , A61K9/146 , A61K9/2054 , A61K9/2077 , A61K9/4858 , A61K9/4866
摘要： An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis -HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要翻译：可口服递送的药物组合物包含作为唯一或第一活性成分的本文定义的式I化合物或其药学上可接受的盐，例如以游离碱当量分散的ABT-263游离碱或ABT-263双-HCl盐至少约2.5重量％的组合物，在药学上可接受的载体中; 其中所述活性成分是固态形式和/或所述组合物还包含以有效抑制活性成分在其硫醚键的氧化的量分散在载体中的药学上可接受的较重硫族元素抗氧化剂。该组合物适合于有需要的受试者的口服给药，用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。

3. 发明申请

WO2011123381A1 ANTIBODIES AGAINST CSF-1R 审中-公开
标题翻译：抗CSF-1R抗体
公开(公告)号：WO2011123381A1
公开(公告)日：2011-10-06
申请号：PCT/US2011/030148
申请日：2011-03-28
申请人： IMCLONE LLC , DOODY, Jacqueline, Francoise , LI, Yanxia
发明人： DOODY, Jacqueline, Francoise , LI, Yanxia
IPC分类号： C07K16/28 , A61K39/395 , C07K16/32 , A61P35/02 , A61P35/00
CPC分类号： C07K16/2866 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/32 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , A61K2300/00
摘要： The invention provides a human antibody that binds human CSF-IR with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional : inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.
摘要翻译：本发明提供以高亲和力结合人CSF-IR的人抗体。本发明的抗体相对于本领域已知的抗体具有多功能性：通过抑制CSF-1R的信号传导，内化和诱导CSF-1R降解并在包括肿瘤，巨噬细胞和单核细胞的细胞中刺激ADCC，具有显着的优点。它们也被证明可以单独治疗白血病，乳腺癌，子宫内膜癌和前列腺癌，或与多西紫杉醇，紫杉醇，赫赛汀或多柔比星组合有效。

4. 发明申请

WO2006052811A2 L-BAND INDUCTIVE OUTPUT TUBE 审中-公开
标题翻译： L带电感输出管
公开(公告)号：WO2006052811A2
公开(公告)日：2006-05-18
申请号：PCT/US2005/040147
申请日：2005-11-03
申请人： COMMUNICATION & POWER INDUSTRIES, INC. , BOHLEN, Heinz, P. , LI, Yanxia , KRZEMINSKI, Paul, A. , DAVIS, Edmund, T. , TORNE, Robert, N.
发明人： BOHLEN, Heinz, P. , LI, Yanxia , KRZEMINSKI, Paul, A. , DAVIS, Edmund, T. , TORNE, Robert, N.
IPC分类号： H01J25/04 , H01J23/00
CPC分类号： H01J25/04 , H01J23/005 , H01J2223/005 , H01J2225/04
摘要： An inductive output tube (IOT) operates in a frequency range above 1000 MHz. An output window may be provided to separate a vacuum, portion of the IOT from an atmospheric pressure portion of the IOT, the output window being surrounded by a cooling air manifold, the manifold including an air input port and a plurality of apertures permitting cooling air to move from the port, through the manifold and into the atmospheric pressure portion of the IOT. The output cavity may include a liquid coolant input port; a lower circular coolant channel coupled to receive liquid coolant from the liquid coolant input port; a vertical coolant channel coupled to receive liquid coolant from the lower circular coolant channel; an upper circular coolant channel coupled to receive liquid coolant from the vertical coolant channel; and a liquid coolant exhaust port coupled to receive liquid coolant from the upper circular coolant channel.
摘要翻译：感应输出管（IOT）在1000 MHz以上的频率范围内工作。可以提供输出窗口以将IOT的真空部分与IOT的大气压部分分离，输出窗被冷却空气歧管包围，歧管包括空气输入端口和允许冷却空气的多个孔从端口移动通过歧管并进入IOT的大气压力部分。输出腔可以包括液体冷却剂输入端口; 下部圆形冷却剂通道，其耦合以从液体冷却剂输入端口接收液体冷却剂; 垂直冷却剂通道，其联接以从下部圆形冷却剂通道接收液体冷却剂; 上部圆形冷却剂通道，其联接以从垂直冷却剂通道接收液体冷却剂; 以及液体冷却剂排出口，其联接以从上部圆形冷却剂通道接收液体冷却剂。

5. 发明申请

WO2010144464A3 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT 审中-公开
标题翻译：含有抗肿瘤药物的固体分散体
公开(公告)号：WO2010144464A3
公开(公告)日：2011-02-24
申请号：PCT/US2010037795
申请日：2010-06-08
申请人： ABBOTT LAB , SCHMITT ERIC A , TONG PING , HEEMSTRA KATHERINE , FISCHER CRISTINA M , WU HUAILIANG , MILLER JONATHAN MARK , LI YANXIA , LAFOUNTAINE JUSTIN S
发明人： SCHMITT ERIC A , TONG PING , HEEMSTRA KATHERINE , FISCHER CRISTINA M , WU HUAILIANG , MILLER JONATHAN MARK , LI YANXIA , LAFOUNTAINE JUSTIN S
IPC分类号： A61K9/00 , A61K9/14 , A61K31/5377
CPC分类号： A61K31/495 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K9/2027 , A61K9/2054 , A61K9/4858 , A61K9/4866 , A61K47/10 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/44
摘要： A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要翻译：促细胞凋亡的固体分散体基本上是非结晶形式包含分散在固体基质中的Bcl-2家族蛋白质抑制化合物，例如ABT-263，其包含（a）药学上可接受的水溶性聚合物载体和（ b）药学上可接受的表面活性剂。制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶形成。该固体分散体适合于需要其的受试者口服给药以治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。

6. 发明申请

WO2010144464A2 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT 审中-公开
标题翻译：含有抗肿瘤药物的固体分散体
公开(公告)号：WO2010144464A2
公开(公告)日：2010-12-16
申请号：PCT/US2010/037795
申请日：2010-06-08
申请人： ABBOTT LABORATORIES , SCHMITT, Eric A. , TONG, Ping , HEEMSTRA, Katherine , FISCHER, Cristina M. , WU, Huailiang , MILLER, Jonathan Mark , LI, Yanxia , LAFOUNTAINE, Justin S.
发明人： SCHMITT, Eric A. , TONG, Ping , HEEMSTRA, Katherine , FISCHER, Cristina M. , WU, Huailiang , MILLER, Jonathan Mark , LI, Yanxia , LAFOUNTAINE, Justin S.
IPC分类号： A61K31/5377 , A61K33/04 , A61K9/14 , A61P35/00
CPC分类号： A61K31/495 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K9/2027 , A61K9/2054 , A61K9/4858 , A61K9/4866 , A61K47/10 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/44
摘要： A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要翻译：促细胞凋亡的固体分散体基本上是非结晶形式包含分散在固体基质中的Bcl-2家族蛋白质抑制化合物，例如ABT-263，其包含（a）药学上可接受的水溶性聚合物载体和（ b）药学上可接受的表面活性剂。制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶形成。该固体分散体适合于需要其的受试者口服给药以治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。

7. 发明申请

WO2006052811A3 L-BAND INDUCTIVE OUTPUT TUBE 审中-公开
标题翻译： L带电感输出管
公开(公告)号：WO2006052811A3
公开(公告)日：2007-04-19
申请号：PCT/US2005040147
申请日：2005-11-03
申请人： COMMUNICATIONS & POWER INDUSTRIES INC , BOHLEN HEINZ P , LI YANXIA , KRZEMINSKI PAUL A , DAVIS EDMUND T , TORNOE ROBERT N
发明人： BOHLEN HEINZ P , LI YANXIA , KRZEMINSKI PAUL A , DAVIS EDMUND T , TORNOE ROBERT N
IPC分类号： H01J25/04 , H01J23/00
CPC分类号： H01J25/04 , H01J23/005 , H01J2223/005 , H01J2225/04
摘要： An inductive output tube (IOT) operates in a frequency range above 1000 MHz. An output window may be provided to separate a vacuum, portion of the IOT from an atmospheric pressure portion of the IOT, the output window being surrounded by a cooling air manifold, the manifold including an air input port and a plurality of apertures permitting cooling air to move from the port, through the manifold and into the atmospheric pressure portion of the IOT. The output cavity may include a liquid coolant input port; a lower circular coolant channel coupled to receive liquid coolant from the liquid coolant input port; a vertical coolant channel coupled to receive liquid coolant from the lower circular coolant channel; an upper circular coolant channel coupled to receive liquid coolant from the vertical coolant channel; and a liquid coolant exhaust port coupled to receive liquid coolant from the upper circular coolant channel.
摘要翻译：感应输出管（IOT）在1000 MHz以上的频率范围内工作。可以提供输出窗口以将IOT的真空部分与IOT的大气压部分分离，输出窗被冷却空气歧管包围，歧管包括空气输入端口和允许冷却空气的多个孔从端口移动通过歧管并进入IOT的大气压力部分。输出腔可以包括液体冷却剂输入端口; 下部圆形冷却剂通道，其耦合以从液体冷却剂输入端口接收液体冷却剂; 垂直冷却剂通道，其联接以从下部圆形冷却剂通道接收液体冷却剂; 上部圆形冷却剂通道，其联接以从垂直冷却剂通道接收液体冷却剂; 以及液体冷却剂排出口，其联接以从上部圆形冷却剂通道接收液体冷却剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式